NYSE:NGM - NGM Biopharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$15.57 +0.17 (+1.10 %)
(As of 04/26/2019 08:00 AM ET)
Previous Close$15.40
Today's Range$15.00 - $16.20
52-Week Range$14.50 - $18.75
Volume35,500 shs
Average Volume169,536 shs
Market Capitalization$1.01 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Receive NGM News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone650-243-5555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees164
Market Cap$1.01 billion
Next Earnings DateN/A
OptionableNot Optionable

NGM Biopharmaceuticals (NYSE:NGM) Frequently Asked Questions

What is NGM Biopharmaceuticals' stock symbol?

NGM Biopharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGM."

Has NGM Biopharmaceuticals been receiving favorable news coverage?

News stories about NGM stock have been trending negative on Friday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NGM Biopharmaceuticals earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future.

What other stocks do shareholders of NGM Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NGM Biopharmaceuticals investors own include Editas Medicine (EDIT), Galectin Therapeutics (GALT), Genocea Biosciences (GNCA), HEXO (HEXO), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), SunOpta (STKL), Aurora Cannabis (ACB), AT&T (T) and Axsome Therapeutics (AXSM).

Who are NGM Biopharmaceuticals' key executives?

NGM Biopharmaceuticals' management team includes the folowing people:
  • Mr. William J. Rieflin, Exec. Chairman of Directors (Age 59)
  • Dr. David J. Woodhouse, CEO, Acting CFO & Director (Age 48)
  • Dr. Aetna Wun Trombley, Pres & COO (Age 40)
  • Dr. Jin-Long Chen, Founder, Chief Scientific Officer & Director (Age 56)
  • Dr. Hui Tian, Sr. VP of Research

When did NGM Biopharmaceuticals IPO?

(NGM) raised $100 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO.

When does the company's quiet period expire?

NGM Biopharmaceuticals' quiet period expires on Tuesday, May 14th. NGM Biopharmaceuticals had issued 6,666,667 shares in its public offering on April 4th. The total size of the offering was $106,666,672 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NGM Biopharmaceuticals' stock price today?

One share of NGM stock can currently be purchased for approximately $15.57.

How big of a company is NGM Biopharmaceuticals?

NGM Biopharmaceuticals has a market capitalization of $1.01 billion. NGM Biopharmaceuticals employs 164 workers across the globe.

What is NGM Biopharmaceuticals' official website?

The official website for NGM Biopharmaceuticals is http://www.ngmbio.com.

How can I contact NGM Biopharmaceuticals?

The company can be reached via phone at 650-243-5555.


MarketBeat Community Rating for NGM Biopharmaceuticals (NYSE NGM)

Community Ranking:  5.0 out of 5 (star star star star star)
Outperform Votes:  1 (Vote Outperform)
Underperform Votes:  0 (Vote Underperform)
Total Votes:  1
MarketBeat's community ratings are surveys of what our community members think about NGM Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Featured Article: Analyst Ratings Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel